CTOs on the Move

Oncocyte

www.oncocyte.com

 
Oncocyte’s mission is to provide tests to physicians and patients that provide answers at critical decision points during lung cancer diagnosis.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.oncocyte.com
  • 1010, Atlantic Avenue
    Alameda, CA USA 94501
  • Phone: 949.409.7600

Executives

Name Title Contact Details

Similar Companies

Allcells LLC

Allcells LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Genelabs Technologies

Genelabs Technologies, Inc. is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Relypsa

Relypsa is a biopharmaceutical company leading the discovery, development and commercialization of polymer-based medicines to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patient lives or even be life-threatening. Relypsa was founded in October 2007 and is headquartered in Redwood City, Calif. In 2015, we received FDA approval for our first medicine, which was developed based on our polymer technology platform for the treatment of hyperkalemia. In September 2016, Relypsa became a Vifor Pharma company. Today, we have more than 400 employees united by a passion for improving people’s lives.

Mandalmed

Mandalmed is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mersana

Mersana is rewriting the rules for immunoconjugate therapies by leveraging our Fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients` lives. Our Fleximer platform allows us to custom design an ADC with specific properties to overcome limitations of current ADC approaches and increase the drug`s chances of effectively attacking a particular cancer. We engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. Because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, Mersana`s ADC therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today`s cancer treatments.